IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

A device to treat urinary incontinence made by US biotech Axonics has been recommended for NHS use by NICE, which says it could save thousands of pounds in healthcare costs. The implantable Axonics ...

Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting-edge ...

The Axonics r-SNM system represents the first rechargeable option for patients with bladder and bowel dysfunction. A company that appears to be well-positioned to take on an industry titan in a ...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has filed a premarket ...

A California jury ruled on Wednesday that Axonics did not infringe three of Medtronic’s patents related to sacral neuromodulation. The latest decision resolves a lawsuit that has been ongoing since ...